LifeScience Biologics
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Op...
July 13, 2026 | News
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Dru...
July 13, 2026 | News
Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi...
July 13, 2026 | News
Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...
July 13, 2026 | Analysis
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist I...
July 13, 2026 | News
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance ma...
July 13, 2026 | News
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the biologics license application (BLA) for Op...
July 13, 2026 | News
Abcam, a Danaher company and a global provider of validated antibodies and assay solutions, and EpiCypher®, the leading provider of ChIC...
July 10, 2026 | News
Partnership with Hamburg Trading Corp to advance applied testing and life science research Serving as a learning hub to empower the next generatio...
July 10, 2026 | News
For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...
July 09, 2026 | Analysis
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
July 09, 2026 | News
OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today an...
July 09, 2026 | News
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Euro...
July 08, 2026 | News
In Songdo and Bengaluru, the numbers finally look like the ones the region was promised a decade ago. Celltrion closed 2025 with revenue above ₩4 trillio...
July 07, 2026 | Analysis
Most Read
Bio Jobs
News
Editor Picks